Article

Cindy Bjorkquist Addresses Engaging Consumers in the Healthcare Marketplace

Conference|AHIP: America's Health Insurance Plans Meetings

Cindy Bjorkquist, Director of Wellness, Care Management and Health Promotion Programs Development, Blue Cross Blue Shield of Michigan, discusses Blue Cross Blue Shield of Michigan's Total Health Improvement Strategy.

Cindy Bjorkquist, Director of Wellness, Care Management and Health Promotion Programs Development, Blue Cross Blue Shield of Michigan, discusses Blue Cross Blue Shield of Michigan's Total Health Improvement Strategy. "It is a strategy to empower individuals and customers with product designs and solutions to help people improve their health," said Ms. Bjorkquist.

Ms. Bjorkquist states that there are 3 parts to the stratgey, including innovative plan design, dedicated health support, and enhanced care delivery.

This video was taken on Monday, December 3, at AHIP's Fall Forum 2012 in Chicago, IL.

Related Videos
Marla Black Morgan, MD, Phoebe Neurology Associates
Toby Maher, MD, PhD, professor of clinical medicine, Keck School of Medicine at USC
Nini Wu, MD, Navista
Matthew Viggiano, MD, internal medicine resident, Temple University Hospital
Krunal Patel, MD, pulmonary and critical care fellow, Temple University Hospital
M. Bradley Drummond, MD, MHS, professor of medicine, University of North Carolina at Chapel Hill
Sanjay Ramakrishnan, MD, senior lecturer, University of Western Australia
Michael Goulet, DO, pulmonary and critical care fellow, Temple University Hospital
Tom Belmon, CAP, GPBCH
Tom Belmont
Related Content
Can GLP-1 Receptor Agonists Curb Cancer? Study Links Drugs to Reduced Risk in Obesity-Related Cases
May 22nd 2025

Can GLP-1 Receptor Agonists Curb Cancer? Study Links Drugs to Reduced Risk in Obesity-Related Cases

Mary Caffrey
Drugs first approved to treat diabetes, which later became a top sellers to aid weight loss, are associated with reduced risk of obesity-related cancer.
Image of Managed Care Cast logo
August 29th 2023

The Importance of Examining and Preventing Atrial Fibrillation

Maggie L. Shaw
At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
In the phase 3 IMforte trial, patients with extensive-stage small cell lung cancer experienced clinically meaningful benefits with maintenance lurbinectedin plus atezolizumab vs atezolizumab. | Image credit: appledesign - stock.adobe.com
May 22nd 2025

Lurbinectedin Plus Atezolizumab Maintenance Shows Improved Survival vs Atezolizumab in SCLC

Rose McNulty
Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin plus atezolizumab vs atezolizumab in the phase 3 IMforte trial, according to findings being presented at the ASCO Annual Meeting.
Managed Care Cast.
June 28th 2022

Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions

Matthew Gavidia
On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Mepolizumab | Image credit: luchschenF – stock.adobe.com
May 20th 2025

Mepolizumab Reduces COPD Exacerbations in Patients With Eosinophilic Inflammation

Hayden E. Klein
New findings from the MATINEE and COPD-HELP studies suggest mepolizumab could reduce exacerbations and improve quality of life in patients with eosinophilic chronic obstructive pulmonary disease (COPD).
Pill and water in hand | Image credit: New Africa – stock.adobe.com
May 20th 2025

FIBRONEER-ILD: Novel PDE4B Inhibitor Slows FVC Decline in Progressive Pulmonary Fibrosis

Hayden E. Klein
Nerandomilast significantly slowed lung function decline and reduced mortality in patients with progressive pulmonary fibrosis (PPF), with consistent efficacy regardless of background antifibrotic therapy.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo